Autoimmune encephalitis is characterized by mental and behavioral symptoms, seizures, and cognitive impairment. The presence of schizophrenia needs to be distinguished from that of autoimmune encephalitis. Herein, we describe the case of a woman who exhibited abnormal mental behavior and cognitive impairment. The patient had experienced similar symptoms more than 20 years previously and had been diagnosed with schizophrenia. The patient's psychotic symptoms improved after treatment with antipsychotic drugs; however, cognitive impairment persisted. She was diagnosed with anti-N-methyl-D-aspartate (NMDA)-receptor concurrent with anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor encephalitis. She showed improvement after treatment with steroids and intravenous immunoglobulins (IVIgs). Furthermore, we reviewed the literature and found that, including the present case, 10 patients have been diagnosed with anti-NMDA concurrent with anti-AMPA-receptor encephalitis. Three of these patients were men and seven were women, and their ages ranged from 21 to 71 years. Moreover, seven (70%) patients had a history of tumors. Symptoms of these patients included psychotic symptoms, varying degrees of consciousness disturbance, seizures, dyskinesia, dystonia, autonomic dysfunction, agitation, and verbal reduction. Brain magnetic resonance imaging findings showed scattered fluid-attenuated inversion recovery hyperintensity in subcortical white matter and/or medial temporal lobe in seven (70%) patients. After combination treatment, including tumor removal and administration of steroids, IVIg, plasma exchange, or immunity inhibitors, the symptoms improved in part of the patients. It is necessary to exclude autoimmune encephalitis for patients with psychiatric manifestations and cognitive impairment. Timely combination therapy is important in anti-NMDA-receptor concurrent with anti-AMPA-receptor encephalitis.
Key Clinical Message: Immunotherapy may be ineffective in the advanced stages of anti‐IgLON5 disease with psychiatric symptoms. The psychiatric symptoms in advanced stages of anti‐IgLON5 disease may be associated with neurodegeneration.
8 October 2025 in Clinical Neurology and Neurosurgery
The Psychiatric Symptoms in Anti-IgLON5 Disease: Case Report and Literature ReviewKey Clinical MessageImmunotherapy may be ineffective in the advanced stages of anti-IgLON5 disease with psychiatric symptoms. The psychiatric symptoms in advanced stages of anti-IgLON5 disease may be associated with neurodegeneration.Keywords: Anti-IgLON5 disease, Psychiatric symptoms, Neurodegeneration, Immunotherapy, Case report.
Partial psychotic disorders such as autoimmune psychosis do not respond adequately to conventional antipsychotic drugs or psychotherapy. Autoimmune psychosis presents with isolated psychiatric symptoms, responds to immunotherapy, and differs from typical autoimmune encephalitis. Previous study has proposed an approach to identifying autoimmune psychosis, however, further research remains necessary to enhance our understanding of this condition. We describe 3 patients presenting with acute or recurrent psychiatric symptoms (patient 1, 2 and 3), accompanied by cognitive impairment (patient 1), autonomic dysfunction (patient 2), and/or abnormal electroencephalogram (patient 1). Brain magnetic resonance imaging results and autoimmune antibodies in cerebrospinal fluid testing were normal. However, the cerebrospinal fluid-restricted oligoclonal bands were detected in patient 1 and patient 2, while patient 3 showed positive tissue-based assay results in cerebrospinal fluid. Combined steroid therapy could enhance the limited improvement in patient 1, who had been treated with blonanserin, valproate and modified electroconvulsive therapy, and could also prevent symptom recurrence in patient 2, who received antipsychotic treatment. In contrast, in the absence of combined steroid therapy, patient 3 had only partial improvement with risperidone and valproate. Cerebrospinal fluid-restricted oligoclonal bands and tissue-based assay in cerebrospinal fluid could both provide sufficient evidence for autoimmune psychosis in the absence of clear neurological symptoms. For patients with mild psychiatric symptoms, low-dose of steroids may also be a treatment option. Autoimmune psychosis should be considered when antipsychotic drugs or modified electroconvulsive therapy are not effective in patients with psychotic disorders.